SV2A and Alzheimer disease: In cohort 1, CSF SV2A was significantly lower in participants with AD (1072 ± 393 pg/mL, n = 20) compared to CU Aβ‐ participants (1679 ± 433 pg/mL, n = 20, unpaired t‐test, p < 0.0001, eFigure 1).